Opens in a new tab

CureVac Manufacturing v Moderna (CFI, 14 September 2026)

Date14 September 2026
CourtCFI
DivisionThe Hague (NL) Local Division
Type of actionInfringement Action
Case number(s)UPC_CFI_1407/2026
Registry referenceUPC-CFI-0001407/2026
PartiesCureVac Manufacturing GmbH v. Moderna, Inc., Moderna Netherlands B.V., Moderna Switzerland GmbH, Moderna Biotech Spain SL, ModernaTX, Inc., Mo…

Official decision (PDF) · UPC registry entry

Case timeline

Dhenne Avocats represents claimants and defendants in European patent disputes before the Unified Patent Court, including the Paris divisions.

Contact the firm

Dhenne Avocats · 10 October 2026

Our analysis

Summary

By order of 11 September 2026, the judge-rapporteur of The Hague Local Division defers Moderna’s preliminary objection on international jurisdiction to the main proceedings, dismisses its Rule 361 request and provisionally grants confidentiality protection limited to the representatives of CureVac Manufacturing GmbH. The order, made in the infringement action on EP 4 108 769, shows that an objection which cannot dispose of the whole action need not be decided at the outset.

Question

Must a preliminary objection directed at certain defendants and at claims concerning non-UPC States be decided immediately, and can those claims be dismissed under Rule 361 RoP?

Decision

Since the objection could lead neither to the dismissal of the whole action for lack of jurisdiction nor to the division lacking competence for the entire case, and since case law in this area is evolving rapidly, the decision is deferred to the main proceedings under Rule 20.2 RoP (paragraph 7). A Rule 361 application, assuming it is admissible within a preliminary objection, is reserved for clear-cut situations. This is not one, and the application is dismissed (paragraph 8). Pending a final order under Rule 262A RoP, the unredacted statement of defence and counterclaim for revocation are available only to CureVac’s representatives and their assistants (paragraphs 9 and 10). The panel also states its intention not to bifurcate under Art. 33(3)(a) UPCA (paragraph 11).

Key points for practice

Provisions applied

Agreement on a Unified Patent Court
Art. 33(3)(a)
Rules of Procedure
Rules 19, 20.2, 262.2, 262A and 361
Case law cited
Aylo v Dish, Court of Appeal, 3 September 2024, on the admissibility of a Rule 361 application within a preliminary objection, Microsoft v Suinno, Court of Appeal, 15 October 2024, on Rule 361 being reserved for clear-cut situations.

Prepared by Dhenne Avocats from the official decision, consulted on 10 October 2026. The database is updated every week, on Friday. Only the official text is authoritative.


Decisions in the same proceedings

Going further

Lexicon: Patent infringement action.

Publications by Matthieu Dhenne: Pleading the Long Arm: What a UPC Statement of Claim Must Carry Beyond Jurisdiction (Kluwer Patent Blog).

Source and translations

Official source
Unified Patent Court registry link recorded in the record
Original language
not recorded
Translation available
no translation recorded the firm’s French record is a summary, not a translation
Date checked
not recorded
Only the official text is authoritative. A machine translation is never presented as official, republishing a third-party document requires a verified basis in rights, and a link to the source is preferred.

Follow this case

Proceedings, related decisions, appeals, parties and patents as recorded in the registry and in the Dhenne Avocats corpus. Each link states its source.

Proceedings

  • UPC_CFI_1407/2026 official number

Follow this case

Parties

Exact name as it appears in the record, group affiliation only where sourced and dated.

Decisions in the same proceedings and documented appeals

  1. 1 July 2026 CureVac Manufacturing v Moderna (CFI, UPC_CFI_1407/2026, 1 July 2026) Infringement Action · UPC_CFI_1407/2026

    La demande de production de preuves, recevable, est rejetée faute de nécessité et de proportionnalité tant que les défenderesses n’ont pas répondu sur la contrefaçon. Les délais convenus sont confirmés.

  2. 14 September 2026 CureVac Manufacturing v Moderna (CFI, 14 September 2026) Infringement Action · UPC_CFI_1407/2026

What the record states

Nature of the act
Infringement Action
Outcome (Dhenne Avocats summary)
L’exception préliminaire de Moderna sur la compétence est renvoyée au fond, sa demande fondée sur la règle 361 est rejetée faute de situation manifeste, et la demande de confidentialité est provisoirement accueillie au profit des seuls représentants de CureVac.
Appeal
No appeal documented in the corpus, this does not mean that no appeal was lodged.
Instance
First-instance decision, whether it has become final is not recorded.

Patents mentioned

Related decisions cited in the analyses

Scope: Dhenne Avocats corpus. Registry-based links are marked “official number”; links derived from the analyses are marked as such. An erroneous link can be withdrawn without deleting any record.

Patents and standards

PublicationRole in the disputeFamilyStandard and declarationPoolSources
EP 4 108 769Mentioned in the analysis (role not qualified)
Also mentioned in 1 other decision(s): CureVac Manufacturing v Moderna (CFI, UPC_CFI_1407/2026, 1 July 2026)
not recordednot recordednot recordedEspacenet
links not checked
mentioned in: Dhenne Avocats analysis
The statuses “asserted in litigation”, “declared essential”, “listed by a pool” and “essentiality examined by a court” are distinct and may coexist. Validity, infringement and technical essentiality are different questions. Scope: patents cited in the decisions of the Dhenne Avocats corpus, with no essentiality score or prediction.

Receive an alert

Weekly summary of new records and substantive updates matching what you follow. Address confirmed by email, unsubscribe at any time, one email per week even where several of your follows match.

Follow

Weekly summary, on Fridays.